← Back to Search

FT500 for Non-Small Cell Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Fate Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 29 and every 8 weeks thereafter through day 366

Awards & highlights

Approved for 20 Other Conditions

All Individual Drugs Already Approved

No Placebo-Only Group

Summary

This trial is testing FT500, a ready-made treatment using special immune cells, in patients with advanced solid tumors. It helps the immune system fight cancer and can work even when other treatments fail.

Eligible Conditions

Non-Small Cell Lung Cancer
Liver Cancer
Microsatellite Instability
Head and Neck Cancers
Solid Tumors
Breast Cancer
Melanoma
Small Cell Lung Cancer
Colorectal Cancer
Pancreatic Cancer
Neuroendocrine Carcinoma
Lymphoma
Kidney Cancer
Bladder Cancer
Cervical Cancer
Stomach Cancer
Squamous Cell Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 29 and every 8 weeks thereafter through day 366

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 29 and every 8 weeks thereafter through day 366

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 29 and every 8 weeks thereafter through day 366 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

The incidence of participants with Dose Limiting Toxicities (DLTs) within each dose level cohort.

Secondary study objectives

Duration of FT500 persistence

Objective-response rate (ORR)

Awards & Highlights

Approved for 20 Other Conditions

This treatment demonstrated efficacy for 20 other conditions.

All Individual Drugs Already Approved

Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: FT500 in Combination with Immune Checkpoint InhibitorExperimental Treatment6 Interventions

FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

Group II: FT500 MonotherapyExperimental Treatment3 Interventions

FT500 administered once weekly for 3 weeks as a monotherapy

Group III: FT500 +IL-2 in Combination with Immune Checkpoint InhibitorExperimental Treatment7 Interventions

FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Cyclophosphamide

FDA approved

Nivolumab

FDA approved

Atezolizumab

FDA approved

Aldesleukin

FDA approved